Déjà vu Mab
Niche platform technology for life cycle maintenance of approved antibody drugs.
Platform method in engineering of the variable region leads to the second generation antibody drug with increased intrinsic target-binding activity, enhanced therapeutic efficacy, and an extended life cycle maintenance advantage.
If you have some similar ideas of Déjà vu Mab project, please feel free to contact our R&D department for further discussion!
Recombinant protein as a Pan Fc Receptor Interacting molecule
Cancer treatment via symbiosis with tumor tissues through slowing down the progression of cancer-triggered cachexia.
Massive antibody mining, an unique platform for accelerating R&D timelines of therapeutic antibodies.
Niche platform technology for life cycle maintenance of approved antibody drugs.
Next generation CAR-T modules.